Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - Proliferative and anti-apoptotic effects

Breast Cancer Research and Treatment

Volumn 56, Issue 1, 1999, Pages 1-10

  Gooch, Jennifer L ^a   Van Den Berg, Carla L ^b   Yee, Douglas ^a,c  

^a Univ of Texas Health Science Center ^*  (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; Breast cancer; Doxorubicin; IGF I; Paclitaxel

Indexed keywords

DNA FRAGMENT; DOXORUBICIN; ESTRADIOL; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL KINASE; SOMATOMEDIN C; TRYPAN BLUE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA STRUCTURE; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0032850369     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006208721167     Document Type: Article

References (31)

1. Kleinberg DL: Role of IGF-I in normal mammary development. Breast Cancer Res Treat 47: 201-208, 1998
2. Werner H, Le Roith D: The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncol 8: 71-92, 1997
3. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis, Biochim Biophys Acta 1332: F105-F126, 1997
4. Resnicoff M, Baserga R: The role of insulin-like growth factor I receptor in transformation and apoptosis. Ann New York Acad Sci 842: 76-81, 1998
5. Yee D, Jackson JG, Weng C-N, Gooch JL, Lee AV: The IGF system in breast cancer. In: Takano K, Hizuka N, Takahashi, S-I (eds), Molecular Mechanisms to Regulate the Activities of Insulin-like Growth Factors, Elsevier, 1998, pp 319-325
6. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton D, Lippman ME, Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50: 48-53, 1990
7. Sell C, Baserga R, Rubin R: Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55: 303-306, 1995
8. Lamm GM, Christofori G: Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells. Cancer Res 58: 801-807, 1998
9. Liu Y, Lehar S, Corvi C, Payne G, O'Connor R: Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res 58: 570-576, 1998
10. O'Connor R, Kauffman-Zeh A, Liu Y, Lehar S, Evans GI, Baserga R, Blattler WA: Identification of domains of the IGF-IR that are required for protection from apoptosis. Mol Cell Biol 17, 1997
11. Guo YS, Houston CW, Thompson JC, Townsend CMJ: Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. Cell Physiol 175: 141-148, 1998
12. Geier A, Beery R, Haimsohn M, Karasik A: Insulin-like growth factor-I inhibits cell death induced by anticancer drugs in the MCF-7 cells: involvement of growth factors in drug resistance. Cancer Invest 13: 480-486, 1995
13. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, Millis RR: The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70: 335-341, 1994
14. Saunders D, Lawrence W, Christensen C, Wappler N, Raun H, Deppe G: Paclitaxel-induced apoptosis in MCF-7 breast cancer cells. Int J Cancer 70: 214-220, 1997
15. Torres K, Horwitz SB: Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 58: 3620-3626, 1998
16. Dufourny B, Alblas J, van Teeffelen HAAM, van Schaik FMA, van der Burgi B, Steenbergh PH, Sussenbach JS: Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 272: 31163-31171, 1997
17. Jackson JG, White MB, Yee D: Insulin receptor-substrate-1 (IRS-1) is the predominant signaling molecule activated by insulin-like growth factor-I (IGF-I), insulin, and interleukin-4 (IL-4) in estrogen receptor positive human breast cancer cells. J Biol Chem 273: 9994-10003, 1998
18. Minshall C, Arkins S, Freund GG, Kelley KW: Requirement for phosphatidylinositol 3-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. J Immunol: 939-947, 1996
19. Kulik G, Klippel A, Weber MJ: Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Bol 17: 1595-1606, 1997
20. Franke TF, Yang S-I, Chan TO, Datta K, Kazauskas A, Morrison DK, Kaplan DR, Tsichlis PN: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF activated phosphatidylinositol 3-kinase. Cell 81: 727-736, 1995
21. Datta SR, Didek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997
22. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XI. Cell 87: 619-628, 1996
23. Twentyman PR, Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987
24. Schiff PB, Horwitz, SB: Taxol stabilizes microtubules in mouse fibroblast cells. PNAS 77, 1980
25. Tewey KM, Rowe TC, Tand L, Halligan BD, Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 1984
26. Dunn SW, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett JC: A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58: 3353-3361, 1998
27. Yu R, Shtil AA, Tan T-H, Roninson IB, Kong A-NT: Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. Cancer Lett 107: 73-81, 1996
28. Wang T-H, Wang H-S, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J: Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways. J Biol Chem 273: 4928-4936, 1998
29. Manfredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94, 1982
30. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, Schiff PB, Sorbara L, Zeheb R: Taxol: mechanisms of action and resistance. Ann New York Acad Sci 466: 733-744, 1986
31. Lee A, Weng C, Jackson J, Yee D: Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endo 152: 39-47, 1997